Tag:
Sam Waksal
Latest Headlines
Latest Headlines
Waksal inks pair of hepatitis C pacts for his start-up
Sam Waksal ( photo ) got a chance to flex his long neglected deal-making muscles with a pair of pacts with Valeant Pharmaceuticals ( $VRX ) that will help the ex-con build up a hepatitis C franchise as
Waksal promises big things for his new drug firm
With his five-year prison stint for insider trading receding in the background, Sam Waksal ( photo ) is back in visionary mode, telling New York Times writer Andrew Pollack that his new biotech company
Waksal making big development plans for his new biotech venture
Whatever else anyone had to say about Sam Waksal ( photo )--and there was always plenty--he had few peers when it comes to touting the prospects of a biotech company. Now with his five-year prison
Waksal back to deal-making mode, snags Three Rivers for $100M
The Wall Street Journal broke the story this morning that Sam Waksal's Kadmon Pharmaceuticals has struck a deal to buy Three Rivers Pharmaceuticals for $100 million as he promises to take what he
Waksal's back, raising $50M for new biotech venture
Here's a scoop: TheStreet's Adam Feuerstein reports that the disgraced former ImClone CEO Sam Waksal has hatched a plan to raise $50 million for a new biotech company that would acquire, develop or
ImClone: Stock buy timing a coincidence
Talk about great timing: new ImClone CEO John Johnson (formerly, yes, of Johnson
More great investment timing by an ImClone CEO
Talk about great timing: new ImClone CEO John Johnson (formerly, yes, of Johnson & Johnson) did his
